Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant

Executive Summary

After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.

You may also be interested in...



White House Touts Public Confidence In FDA Safety Decisions As It Aims To Expand Vaccinations

Public confidence in the Johnson & Johnson vaccine may be shaken. But faith in the regulatory system is solid, according to a recent poll, an Administration official maintained.

Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders

Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.

J&J COVID-19 Vaccine Rollout Resumes In EU With New Rare Blood Clot Warning

Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel